Little has been known about the immune signature of ATRX-wt glioma, but we found that ATRX-wt patients with low risk scores tended to have higher levels of M1 and CD8+ T cells, suggesting that these infiltrating cells were able to kill cancer cells. This evidence concerns the gene CD8A and central nervous system cancer.